{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:09:04Z","timestamp":1790251744265,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03059-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:10:51Z","timestamp":1784189451000},"page":"2157-2166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial"],"prefix":"10.1038","volume":"40","author":[{"given":"Hailing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-7140","authenticated-orcid":false,"given":"Lixia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-4987","authenticated-orcid":false,"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3059_CR1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology: B-cell lymphomas. Version 3.2025. August 18, (2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"3059_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","volume":"36","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F, de Leval L, Dreyling M, Eichenauer DA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:1263\u201384.","journal-title":"Ann Oncol"},{"key":"3059_CR3","first-page":"153","volume":"66","author":"M Raderer","year":"2016","unstructured":"Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66:153\u201371.","journal-title":"CA Cancer J Clin"},{"key":"3059_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1182\/blood.2024025794","volume":"145","author":"MQ Du","year":"2025","unstructured":"Du MQ. EMZL at various sites: learning from each other. Blood. 2025;145:2117\u201327.","journal-title":"Blood"},{"key":"3059_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","volume":"95","author":"C Thieblemont","year":"2000","unstructured":"Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802\u20136.","journal-title":"Blood"},{"key":"3059_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","volume":"28","author":"S Teckie","year":"2017","unstructured":"Teckie S, Qi S, Chelius M, Lovie S, Hsu M, Noy A, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28:1064\u20139.","journal-title":"Ann Oncol"},{"key":"3059_CR7","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ijrobp.2020.11.070","volume":"109","author":"P Fang","year":"2021","unstructured":"Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, et al. A prospective trial of radiation therapy efficacy and toxicity for localized mucosa-associated lymphoid tissue (MALT) lymphoma. Int J Radiat Oncol Biol Phys. 2021;109:1414\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3059_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","volume":"92","author":"S Teckie","year":"2015","unstructured":"Teckie S, Qi S, Lovie S, Navarrett S, Hsu M, Noy A, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92:130\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3059_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"key":"3059_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ijrobp.2019.02.002","volume":"104","author":"CC Pinnix","year":"2019","unstructured":"Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, et al. Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Int J Radiat Oncol Biol Phys. 2019;104:447\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3059_CR11","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","volume":"21","author":"RW Tsang","year":"2003","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157\u201364.","journal-title":"J Clin Oncol"},{"key":"3059_CR12","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","volume":"11","author":"M Raderer","year":"2005","unstructured":"Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res. 2005;11:3349\u201352.","journal-title":"Clin Cancer Res"},{"key":"3059_CR13","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/cncr.25226","volume":"116","author":"JS Goda","year":"2010","unstructured":"Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815\u201324.","journal-title":"Cancer"},{"key":"3059_CR14","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi A, Martinelli G, Thi\u00e9blemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741\u20135.","journal-title":"Blood"},{"key":"3059_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3059_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.ijrobp.2007.04.029","volume":"69","author":"K Isobe","year":"2007","unstructured":"Isobe K, Kagami Y, Higuchi K, Kodaira T, Hasegawa M, Shikama N, et al. A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys. 2007;69:1181\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3059_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","volume":"23","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin\u2019s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979\u201383.","journal-title":"J Clin Oncol"},{"key":"3059_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000074641","volume":"65","author":"M Raderer","year":"2003","unstructured":"Raderer M, J\u00e4ger G, Brugger S, P\u00fcsp\u00f6k A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65:306\u201310.","journal-title":"Oncology"},{"key":"3059_CR19","doi-asserted-by":"publisher","first-page":"adv00383","DOI":"10.2340\/00015555-3746","volume":"101","author":"S Porkert","year":"2021","unstructured":"Porkert S, Mai P, Jonak C, Weihsengruber F, Rappersberger K, Bauer W, et al. Long-term Therapeutic success of intravenous rituximab in 26 patients with indolent primary cutaneous B-cell lymphoma. Acta Derm Venereol. 2021;101:adv00383.","journal-title":"Acta Derm Venereol"},{"key":"3059_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/cam4.2681","volume":"9","author":"T Zhang","year":"2020","unstructured":"Zhang T, Wu Y, Ju H, Meng J, Guo W, Ren G. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. Cancer Med. 2020;9:194\u2013203.","journal-title":"Cancer Med"},{"key":"3059_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0167-5699(99)01468-1","volume":"20","author":"P Brandtzaeg","year":"1999","unstructured":"Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today. 1999;20:267\u201377.","journal-title":"Immunol Today"},{"key":"3059_CR22","first-page":"1361","volume":"151","author":"A Dogan","year":"1997","unstructured":"Dogan A, Du M, Koulis A, Briskin MJ, Isaacson PG. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol. 1997;151:1361\u20139.","journal-title":"Am J Pathol"},{"key":"3059_CR23","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood.V95.6.1900","volume":"95","author":"P Drillenburg","year":"2000","unstructured":"Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900\u201310.","journal-title":"Blood"},{"key":"3059_CR24","doi-asserted-by":"crossref","unstructured":"Gordon RA, McCoy SS. Sj\u00f6gren disease-B cells at the brink: from autoimmunity to lymphomagenesis and the rise of novel B cell-targeted therapies. Arthritis Rheumatol. 2026;78:1393\u20131402.","DOI":"10.1002\/art.43404"},{"key":"3059_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107565","volume":"95","author":"Z Zian","year":"2021","unstructured":"Zian Z, Berry SPD, Bahmaie N, Ghotbi D, Kashif A, Madkaikar M, et al. The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. Int Immunopharmacol. 2021;95:107565.","journal-title":"Int Immunopharmacol"},{"key":"3059_CR26","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","volume":"121","author":"D Rudnicka","year":"2013","unstructured":"Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121:4694\u2013702.","journal-title":"Blood"},{"key":"3059_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","volume":"27","author":"L Murray","year":"2015","unstructured":"Murray L, Sethugavalar B, Robertshaw H, Bayman E, Thomas E, Gilson D, et al. Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks. Clin Oncol (R Coll Radio). 2015;27:401\u201310.","journal-title":"Clin Oncol (R Coll Radio)"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03059-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03059-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03059-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:34Z","timestamp":1790250214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03059-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3059"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03059-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}